In June 2011, Edison Pharmaceuticals announced preliminary results from a 28-day phase 2a clinical trial of its experimental compound EPI-A0001 in FA. Edison said there was a significant improvement in neurological function as assessed by Friedreich’s Ataxia Rating Scale in people who received the drug compared to those who received a placebo. The company said additional trials will be required to determine the safety and effectiveness of EPI-A0001. The drug is designed to improve energy production in mitochondria.
Voices of Friedreich's Ataxia (FA)
We Have the Power to Overcome Anything, Together!